Retinoids, which are vitamin A derivatives, interact through retinoic acid receptors (RARs) and retinoid X receptors (RXRs) and have profound effects on several physiological and pathological processes in the brain. The presence of retinoic acid signaling is extensively detected in the adult central nervous system, including the amygdala, cortex, hypothalamus, hippocampus, and other brain areas. Retinoids are primarily involved in neural patterning, differentiation, and axon outgrowth. Retinoids also play a key role in the preservation of the differentiated state of adult neurons. Impairment in retinoic acid signaling can result in neurodegeneration and progression of Alzheimer’s disease (AD). Recent studies demonstrated severe deficiencies in spatial learning and memory in mice during retinoic acid (vitamin A) deprivation indicating its significance in preserving memory function. Defective cholinergic neurotransmission plays an important role in cognitive deficits in AD. All-trans retinoic acid is known to enhance the expression and activity of choline acetyltransferase in neuronal cell lines. Activation of RAR and RXR is also known to impede the pathogenesis of AD in mice by inhibiting accumulation of amyloids. In addition, retinoids have been shown to inhibit the expression of chemokines and pro-inflammatory cytokines in microglia and astrocytes, which are activated in AD. In this review article, we have described the chemistry and molecular signaling mechanisms of natural and synthetic retinoids and current understandings of their therapeutic potentials in prevention of AD pathology.
QuerfurthHW, LaFerlaFM (2010) Alzheimer’s disease. N Engl J Med362, 329–344.
4.
ThalDR, WalterJ, SaidoTC, FändrichM (2015) Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease. Acta Neuropathol129, 167–182.
5.
SelkoeDJ, PodlisnyMB (2002) Deciphering the genetic basis of Alzheimer’s disease. Annu Rev Genomics Hum Genet3, 67–99.
6.
HaassC, SelkoeDJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol8, 101–112.
7.
HampelH (2012) Current insights into the pathophysiology of Alzheimer’s disease: Selecting targets for early therapeutic intervention. Int Psychogeriatr24, S10–S17.
8.
Wyss-CorayT, MuckeL (2002) Inflammation in neurodegenerative disease - a double-edged sword. Neuron35, 419–432.
ZlokovicBV (2013) Cerebrovascular effects of apolipoprotein E: Implications for Alzheimer’s disease. JAMA Neurol70, 440–444.
14.
LernerAJ, Gustaw-RothenbergK, SmythS, CasadesusG (2012) Retinoids for treatment of Alzheimer’s disease. Biofactors38, 84–89.
15.
GoodmanAB (2006) Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer’s disease. J Cell Physiol209, 598–603.
16.
GoodmanAB, PardeeAB (2003) Evidence for defective retinoid transport and function in late onset Alzheimer’s disease. Proc Natl Acad Sci U S A100, 2901–2905.
17.
ShudoK, FukasawaH, NakagomiM, YamagataN (2009) Towards retinoid therapy for Alzheimer’s disease. Curr Alzheimer Res6, 302–311.
18.
LeeHP, CasadesusG, ZhuX, LeeHG, PerryG, SmithMA, Gustaw-RothenbergK, LernerA (2009) All-trans retinoic acid as a novel therapeutic strategy for Alzheimer’s disease. Expert Rev Neurother9, 1615–1621.
19.
GoncalvesMB, ClarkeE, HobbsC, MalmqvistT, DeaconR, JackJ, CorcoranJP (2013) Amyloid β inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor α agonist. Eur J Neurosci37, 1182–1192.
20.
MufsonEJ, CountsSE, PerezSE, GinsbergSD (2008) Cholinergic system during the progression of Alzheimer’s disease: Therapeutic implications. Expert Rev Neurother8, 1703–1718.
21.
HymanBT, PhelpsCH, BeachTG, BigioEH, CairnsNJ, CarrilloMC, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, ThiesB, TrojanowskiJQ, VintersHV, MontineTJ (2012) National institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement8, 1–13.
22.
WetzelR (2006) Kinetics and thermodynamics of amyloid fibril assembly. Acc Chem Res39, 671–679.
23.
MakinOS, AtkinsE, SikorskiP, JohanssonJ, SerpellLC (2005) Molecular basis for amyloid fibril formation and stability. Proc Natl Acad Sci U S A102, 315–320.
24.
KodaliR, WetzelR (2007) Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struct Biol17, 48–57.
25.
WalshDM, SelkoeDJ (2007) Aβ oligomers - A decade of discovery. J Neurochem101, 1172–1184.
26.
GesselMM, BernsteinS, KemperM, TeplowDB, BowersMT (2012) Familial Alzheimer’s disease mutations differentially alter amyloid β- protein oligomerization. ACS Chem Neurosci3, 909–918.
27.
WalshDM, LomakinA, BenedekGB, CondronMM, TeplowDB (1997) Amyloid β-protein fibrillogenesis: Detection of a protofibrillar intermediate. J Biol Chem272, 22364–22372.
28.
HabichtG, HauptC, FriedrichRP, HortschanskyP, SachseC, MeinhardtJ, WieligmannK, GellermannGP, BrodhunM, GötzJ, HalbhuberKJ, RöckenC, HornU, FändrichM (2007) Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils. Proc Natl Acad Sci U S A104, 19232–19237.
KrafftGA, KleinWL (2010) ADDLs and the signaling web that leads to Alzheimer’s disease. Neuropharmacol59, 230–242.
32.
KumarA, PaslayLC, LyonsD, MorganSE, CorreiaJJ, RangachariV (2012) Specific soluble oligomers of amyloid-beta peptide undergo replication and form non-fibrillar aggregates in interfacial environments. J Biol Chem287, 21253–21264.
33.
Rijal UpadhayaA, Capetillo-ZarateE, KosterinI (2012) Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: Their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice. Neurobiol Aging33, 2641–2660.
34.
Rijal UpadhayaA, KosterinI, KumarS, von ArnimCA, YamaguchiH, FändrichM, WalterJ, ThalDR (2014) Biochemical stages of amyloid β-peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer’s disease. Brain137, 887–903.
35.
KhillanJS (2014) Vitamin A/retinol and maintenance of pluripotency of stem cells. Nutrients6, 1209–1222.
36.
BaruaAB, FurrHC (1998) Properties of retinoids. Structure, handling, and preparation. Mol Biotechnol10, 167–182.
37.
FurrHC (2004) Analysis of retinoids and carotenoids: Problems resolved and unsolved. J Nutr134, 281S–285S.
38.
MaerckerA (1965) The Wittig reaction. Org React14, 270–490.
39.
JuliaM, ArnouldD (1973) Use of sulfones in synthesis. III. Synthesis of vitamin A. Bull Soc Chim Fr746–750.
40.
KochD, GartnerW (1997) Steric hindrance between chromophore substituents as the driving force of rhodopsin isomerization: 10-methyl-13-demethyl retinal containing rhodopsin. Photochem Photobiol65, 181–186.
41.
AltucciL, LeibowitzMD, OgilvieKM, de LeraAR, GronemeyerH (2007) RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov6, 793–810.
42.
le MaireA, AlvarezS, ShankaranarayananP, LeraAR, BourguetW, GronemeyerH (2012) Retinoid receptors and therapeutic applications of RAR/RXR modulators. Curr Top Med Chem12, 505–527.
43.
DasBC, ThapaP, KarkiR, DasS, MahapatraS, LiuTC, TorregrozaI, WallaceDP, KambhampatiS, Van VeldhuizenP, VermaA, RaySK, EvansT (2014) Retinoic acid signaling pathways in development and diseases. Bioorg Med Chem22, 673–683.
44.
Stephens-JarnaginA, MillerDA, DeLucaHF (1985) The growth supporting activity of a retinoidal benzoic acid derivative and 4,4-difluororetinoic acid. ArchBiochem Biophys237, 11–16.
45.
KagechikaH, ShudoK (2005) Synthetic retinoids: Recent developments concerning structure and clinical utility. J Med Chem48, 5875–5883.
46.
AnguianoJ, GarnerTP, MahalingamM, DasBC, GavathiotisE, CuervoAM (2013) Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives. Nat Chem Biol9, 374–382.
47.
CorcoranJP, SoPL, MadenM (2004) Disruption of the retinoid signalling pathway causes a deposition of amyloid β in the adult rat brain. Eur J Neurosci20, 896–902.
48.
HussonM, EnderlinV, DelacourteA, GhenimiN, AlfosS, PalletV, HigueretP (2006) Retinoic acid normalizes nuclear receptor mediated hypo-expression of proteins involved in beta-amyloid deposits in the cerebral cortex of vitamin A deprived rats. Neurobiol Dis23, 1–10.
49.
MauryCPJ, TeppoAM (1987) Immunodetection of protein composition in cerebral amyloid extracts in Alzheimer’s disease: Enrichment of retinol-binding protein. J Neurol Sci80, 221–228.
50.
LahiriDK, NallC (1995) Promoter activity of the gene encoding the β-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Brain Res Mol Brain Res32, 233–240.
51.
YangY, QuitschkeWW, BrewerGJ (1998) Upregulation of amyloid precursor protein gene promoter in rat primary hippocampal neurons by phorbol ester, IL-1 and retinoic acid, but not by reactive oxygen species. Mol Brain Res60, 40–49.
52.
FahrenholzF, PostinaR (2006) α-secretase activation - an approach to Alzheimer’s disease therapy. Neurodegener Dis3, 255–261.
53.
SatohJ, KurodaY (2000) Amyloid precursor protein beta -secretase (BACE) mRNA expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines and growth factors. Neuropathology20, 289–296.
54.
YoshikawaK, AizawaT, HayashiY (1992) Degeneration in vitro of post-mitotic neurons overexpressing the Alzheimer amyloid protein precursor. Nature359, 64–67.
55.
OnoK, YoshiikeY, TakashimaA, HasegawaK, NaikiH, YamadaM (2004) Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol189, 380–392.
56.
WhitehousePJ, PriceDL, StrubleRG, ClarkAW, CoyleJT, DelonMR (1982) Alzheimer’s disease and senile dementia: Loss of neurons in the basal forebrain. Science215, 1237–1239.
ColemanBA, TaylorP (1996) Regulation of acetylcholinesterase expression during neuronal differentiation. J Biol Chem271, 4410–4416.
59.
HillDR, RobertsonKA (1997) Characterisation of the colinergic neuronal differentiation of the human neuroblastoma cell line LAN-5 after treatment with retinoic acid. Dev Brain Res102, 53–67.
60.
Grapin-BottonA, BonninMA, SiewekeM, Le DouarinNM (1998) Defined concentrations of a posteriorizing signal are critical for MafB/Kreisler segmental expression in the hindbrain. Development125, 1173–1181.
61.
ObulesuM, DowlathabadMR, BramhachariPV (2011) Carotenoids and Alzheimer’s disease: An insight into therapeutic role of retinoids in animal models. Neurochem Int59, 535–541.
62.
MadenM (2007) Retinoic acid in the development, regeneration and maintenance of the nervous system. Nat Rev Neurosci8, 755–765.
63.
PaulsonJB, RamsdenM, ForsterC, ShermanMA, McGowanE, AsheKH (2008) Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer’s disease. Am J Pathol173, 762–772.
64.
TakasakiJ, OnoK, YoshiikeY, HirohataM, IkedaT, MorinagaA, TakashimaA, YamadaM (2011) Vitamin A has anti-oligomerization effects on amyloid-β in vitro. J Alzheimers Dis27, 271–280.
65.
JarvisCI, GoncalvesMB, ClarkeE, DogruelM, KalindjianSB, ThomasSA, MadenM, CorcoranJP (2010) Retinoic acid receptor-α signalling antagonizes both intracellular and extracellular amyloid-β production and prevents neuronal cell death caused by amyloid-β. Eur J Neurosci32, 1246–1255.
66.
DingY, QiaoA, WangZ, GoodwinJS, LeeES, BlockML, AllsbrookM, McDonaldMP, FanGH (2008) Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer’s disease transgenic mouse model. J Neurosci28, 11622–11634.
67.
KoryakinaA, AeberhardJ, KieferS, HamburgerM, KüenziP (2009) Regulation of secretases by all-trans-retinoic acid. FEBS J276, 2645–2655.
68.
FukasawaH, NakagomiM, YamagataN, KatsukiH, KawaharaK, KitaokaK, MikiT, ShudoK (2012) Tamibarotene: A candidate retinoid drug for Alzheimer’s disease. Biol Pharm Bull35, 1206–1212.
69.
MelinoG, DraouiM, BernardiniS, BellincampiL, ReichertU, CohenP (1996) Regulation by retinoic acid of insulin-degrading enzyme and of a related endoprotease in human neuroblastoma cell lines. Cell Growth Differ7, 787–796.
70.
CorbettA, PickettJ, BurnsA, CorcoranJ, DunnettSB, EdisonP, HaganJJ, HolmesC, JonesE, KatonaC, KearnsI, KehoeP, MudherA, PassmoreA, ShepherdN, WalshF, BallardC (2012) Drug repositioning for Alzheimer’s disease. Nat Rev Drug Discov11, 833–846.
71.
ChawlaA, BoisvertWA, LeeCH, LaffitteBA, BarakY, JosephSB, LiaoD, NagyL, EdwardsPA, CurtissLK, EvansRM, TontonozP (2001) A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell7, 161–171.
72.
Mandrekar-ColucciS, LandrethGE (2011) Nuclear receptors as therapeutic targets for Alzheimer’s disease. Expert Opin Ther Targets15, 1085–1097.
73.
EstevaFJ, GlaspyJ, BaidasS, LaufmanL, HutchinsL, DicklerM, TripathyD, CohenR, DeMicheleA, YocumRC, OsborneCK, HayesDF, HortobagyiGN, WinerE, DemetriGD (2003) Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol21, 999–1006.
74.
DragnevKH, PettyWJ, ShahSJ, LewisLD, BlackCC, MemoliV, NugentWC, HermannT, Negro-VilarA, RigasJR, DmitrovskyE (2007) A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res13, 1794–1800.
75.
TousiB (2015) The emerging role of bexarotene in the treatment of Alzheimer’s disease: Current evidence. Neuropsychiatr Dis Treat11, 311–315.
76.
CramerPE, CirritoJR, WessonDW, LeeCY, KarloJC, ZinnAE, CasaliBT, RestivoJL, GoebelWD, JamesMJ, BrundenKR, WilsonDA, LandrethGE (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science335, 1503–1506.
77.
FitzNF, CronicanAA, LefterovI, KoldamovaR (2013) Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”. Science340, 924c.
78.
PriceAR, XuG, SiemienskiZB, SmithsonLA, BorcheltDR, GoldeTE (2013) Felsenstein KM. Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”.. Science340, 924d.
79.
VeeraraghavaluK, ZhangC, MillerS, HefendehlJK, RajapakshaTW, UlrichJ, JuckerM, HoltzmanDM, TanziRE, VassarR, SisodiaSS (2013) Comment on“ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”.. Science340, 924f.
80.
Collins, ThomasR (2014) News from the ANN annual meeting: RXR agonist shows potential for myelin repair in vitro, new study suggests. Neurology Today14, 22–23.
81.
JohnstonH, BoutinH, AllanSM (2011) Assessing the contribution of inflammation in models of Alzheimer’s disease. Biochem Soc Trans39, 886–890.
82.
WeitzTM, TownT (2012) Microglia in Alzheimer’s disease: It’s all about context. Int J Alzheimers Dis2012, 314185.
83.
FialaM, LinJ, RingmanJ, Kermani-ArabV, TsaoG, PatelA, LossinskyAS, GravesMC, GustavsonA, SayreJ, SofroniE, SuarezT, ChiappelliF, BernardG (2005) Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer’s disease patients. J Alzheimers Dis7, 221–232.
84.
KuenzliS, TranC, SauratJH (2004) Retinoid receptors in inflammatory responses: A potential target for pharmacology. Curr Drug Targets Inflamm Allergy3, 355–360.
85.
ZitnikRJ, KotloffRM, LatifpourJ, ZhengT, WhitingNL, SchwalbJ, EliasJA (1994) Retinoic acid inhibition of IL-1-induced IL-6 production by human lung fibroblasts. J Immunol152, 1419–1427.
86.
KagechikaH, KawachiE, FukasawaH, SaitoG, IwanamiN, UmemiyaH, HashimotoY, ShudoK (1997) Inhibition of IL-1-induced IL-6 production by synthetic retinoids. Biochem Biophys Res Commun231, 243–248.
87.
DheenST, JunY, YanZ, TaySS, LingEA (2005) Retinoic acid inhibits expression of TNF-alpha and iNOS in activated rat microglia. Glia50, 21–31.
88.
KaurC, SivakumarV, DheenST, LingEA (2006) Insulin-like growth factor I and II expression and modulation in amoeboid microglial cells by lipopolysaccharide and retinoic acid. Neuroscience138, 1233–1244.
89.
CarratúMR, MarascoC, SignorileA, ScuderiC, SteardoL (2012) Are retinoids a promise for Alzheimer’s disease management?. Curr Med Chem19, 6119–6125.
KampmannE, JohannS, van NeervenS, BeyerC, MeyJ (2008) Anti-inflammatory effect of retinoic acid on prostaglandin synthesis in cultured cortical astrocytes. J Neurochem106, 320–332.
92.
GabbitaSP, LovellMA, MarkesberyWR (1998) Increased nuclear DNA oxidation in the brain in Alzheimer’s disease. J Neurochem71, 2034–2040.
93.
NunomuraA, PerryG, PappollaMA, WadeR, HiraiK, ChibaS, SmithMA (1999) RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer’s disease. J Neurosci19, 1959–1964.
94.
NunomuraA, PerryG, AlievG (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol60, 759–767.
95.
ShigenagaMK, HagenTM, AmesBN (1994) Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A91, 10771–10778.
96.
TamagnoE, BardiniP, ObbiliA, VitaliA, BorghiR, ZaccheoD, PronzatoMA, DanniO, SmithMA, PerryG, TabatonM (2002) Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis10, 279–288.
97.
GaspariniL, RacchiM, BenussiL, CurtiD, BinettiG, BianchettiA, TrabucchiM, GovoniS (1997) Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci Lett231, 113–117.
98.
WebsterMT, PearceBR, BowenDM, FrancisPT (1998) The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. J Neural Transm105, 839–853.
99.
ManczakM, AnekondaTS, HensonE, ParkBS, QuinnJ, ReddyPH (2006) Mitochondria are a direct site of Aβ accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet15, 1437–1449.
100.
RuiY, TiwariP, XieZ, ZhengJQ (2006) Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons. J Neurosci26, 10480–10487.
PetersonC, GoldmanJE (1986) Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci U S A83, 2758–2762.
103.
SaraivaAA, BorgesMM, MadeiraMD, TavaresMA, Paula-BarbosaMM (1985) Mitochondrial abnormalities in cortical dendrites from patients with Alzheimer’s disease. J Submicrosc Cytol17, 459–464.
104.
GibsonGE, SheuKF, BlassJP, BakerA, CarlsonKC, HardingB, PerrinoP (1988) Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer’s disease. Arch Neurol45, 836–840.
105.
BlassJP, GibsonGE, HoyerS (2002) The role of the metabolic lesion in Alzheimer’s disease. J Alzheimers Dis4, 225–232.
106.
PraticòD, UryuK, LeightS, TrojanoswkiJQ, LeeVM (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci21, 4183–4187.
107.
NunomuraA, CastellaniRJ, ZhuX, MoreiraPI, PerryG, SmithMA (2006) Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol65, 631–641.
108.
AhlemeyerB, HühneR, KrieglsteinJ (2000) Retinoic acid potentiated the protective effect of NGF against staurosporine-induced apoptosis in cultured chick neurons by increasing the trkA protein expression. J Neurosci Res60, 767–778.
109.
AhlemeyerB, BauerbachE, PlathM, SteuberM, HeersC, TegtmeierF, KrieglsteinJ (2001) Retinoic acid reduces apoptosis and oxidative stress by preservation of SOD protein level. Free Radic Biol Med30, 1067–1077.
110.
St George-HyslopPH (2000) Piecing together Alzheimer’s disease. Sci Am283, 76–83.
TrilloL, DasD, HsiehW, MedinaB, MoghadamS, LinB, DangV, SanchezMM, De MiguelZ, AshfordJW, SalehiA (2013) Ascending monoaminergic systems alterations in Alzheimer’s disease. translating basic science into clinical care. Neurosci Biobehav Rev37, 1363–1379.
113.
VengLM, GranholmAC, RoseGM (2003) Age-related sex differences in spatial learning and basal forebrain cholinergic neurons in F344 rats. Physiol Behav80, 27–36.
114.
HunterCL, Bimonte-NelsonHA, NelsonM, EckmanCB, GranholmAC (2004) Behavioral and neurobiological markers of Alzheimer’s disease in Ts65Dn mice: Effects of estrogen. Neurobiol Aging25, 873–884.
115.
SantucciAC, KanofPD, HaroutunianV (1989) Effect of physostigmine on memory consolidation and retrieval processes in intact and nucleus basalis-lesioned rats. Psychopharmacology (Berl)99, 70–74.
116.
BerseB, BlusztajnJK (1995) Coordinated up-regulation of choline acetyltransferase and vesicular acetylcholine transporter gene expression by the retinoic acid receptor alpha, cAMP, and leukemia inhibitory factor/ciliary neurotrophic factor signaling pathways in a murine septal cell line. J Biol Chem270, 22101–22104.
117.
KobayashiM, MatsuokaI, KuriharaK (1994) Cholinergic differentiation of cultured sympathetic neurons induced by retinoic acid. Induction of choline acetyltransferase-mRNA and suppression of tyrosine hydroxylase-mRNA levels. FEBS Lett337, 259–264.
118.
PedersenWA, BerseB, SchülerU, WainerBH, BlusztajnJK (1995) All-trans- and 9-cis-retinoic acid enhance the cholinergic properties of a murine septal cell line: Evidence that the effects are mediated by activation of retinoic acid receptor-alpha. J Neurochem65, 50–58.
119.
MannDM, LincolnJ, YatesPO, StampJE, ToperS (1980) Changes in the monoamine containing neurones of the human CNS in senile dementia. Br J Psychiatry136, 533–541.
120.
IversenLL, RossorMN, ReynoldsGP, HillsR, RothM, MountjoyCQ, FooteSL, MorrisonJH, BloomFE (1983) Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer’s type. Neurosci Lett39, 95–100.
121.
ReinikainenKJ, PaljärviL, HuuskonenM, SoininenH, LaaksoM, RiekkinenPJ (1988) A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer’s disease. J Neurol Sci84, 101–116.
122.
StorgaD, VreckoK, BirkmayerJG, ReibneggerG (1996) Monoaminergic neurotransmitters,their precursors and metabolites in brains of Alzheimer patients. Neurosci Lett203, 29–32.
123.
PinessiL, RaineroI, De GennaroT, GentileS, PortaleoneP, BergamascoB (1987) Biogenic amines in cerebrospinal fluid and plasma of patients with dementia of Alzheimer’s type. Funct Neurol2, 51–58.
PizzolatoG, ChierichettiF, FabbriM, CagninA, DamM, FerlinG, BattistinL (1996) Reduced striatal dopamine receptors in Alzheimer’s disease: Single photon emission tomography study with the D2 tracer [123I]-IBZM. Neurology47, 1065–1068.
126.
KemppainenN, RuottinenH, NâgrenK, RinneJO (2000) PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology55, 205–209.
127.
KimHS, HongSJ, LeDouxMS, KimKS (2001) Regulation of the tyrosine hydroxylase and dopamine beta-hydroxylase genes by the transcription factor AP-2. J Neurochem76, 280–294.
128.
SamadTA, KrezelW, ChambonP, BorrelliE (1997) Regu1lation of dopaminergic pathways by retinoids: Activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. Proc Natl Acad Sci U S A94, 14349–14354.
129.
LalumiereRT, NguyenLT, McGaughJL (2004) Post-training intrabasolateral amygdala infusions of dopamine modulate consolidation of inhibitory avoidance memory: Involvement of noradrenergic and cholinergic systems. Eur J Neurosci20, 2804–2810.
130.
McGaughJL (2004) The amygdala modulates the consolidation of memories of emotionally arousing experiences. Annu Rev Neurosci27, 1–28.
131.
MadenM (2006) Retinoids and spinal cord development. J Neurobiol66, 726–738.
132.
StricklandS, MahdaviV (1978) The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell15, 393–403.
133.
WongLF, YipPK, BattagliaA, GristJ, CorcoranJ, MadenM, AzzouzM, KingsmanSM, KingsmanAJ, MazarakisND, McMahonSB (2006) Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord. Nat Neurosci9, 243–250.
134.
CorcoranJ, SoPL, BarberRD, VincentKJ, MazarakisND, MitrophanousKA, KingsmanSM, MadenM (2002) Retinoic acid receptor beta2 and neurite outgrowth in the adult mouse spinal cord in vitro. J Cell Sci115, 3779–3786.
DubieT, AdmassuB, SisayT, ShiferawH (2014) Basicbiology and therapeutic application of stem cells in various human and animal diseases. J Cell Biol Genet4, 40–52.
137.
YokooT, FukuiA, KobayashiE (2007) Application of regenerative medicine for kidney diseases. Organogenesis3, 34–43.
138.
ChristieVB, BarnardJH, BatsanovAS, BridgensCE, CartmellEB, CollingsJC, MaltmanDJ, RedfernCP, MarderTB, PrzyborskiS, WhitingA (2008) Synthesis and evaluation of synthetic retinoid derivatives as inducers of stem cell differentiation. Org Biomol Chem6, 3497–3507.
139.
DaftarianN, KianiS, ZahabiA (2010) Regenerative therapy for retinal disorders. J Ophthalmic Vis Res5, 250–264.
JaturapatpornD, IsaacMG, McCleeryJ, TabetN (2012) Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev2, CD006378.
147.
LullME, LevesqueS, SuraceMJ, BlockML (2011) Chronic apocynin treatment attenuates beta amyloid plaque size and microglial number in hAPP(751)(SL) mice. PLoS One6, e20153.
148.
MaoP, ManczakM, CalkinsMJ, TruongQ, ReddyTP, ReddyAP, ShirendebU, LoHH, RabinovitchPS, ReddyPH (2012) Mitochondria-targeted catalase reduces abnormal APP processing, amyloid beta production and BACE1 in a mouse model of Alzheimer’s disease: Implications for neuroprotection and lifespan extension. Hum Mol Genet21, 2973–2990.
149.
LiC, EbrahimiA, SchluesenerH (2013) Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer’s disease. Ageing Res Rev12, 116–140.
150.
ShiY, KirwanP, SmithJ, MacleanG, OrkinSH, LiveseyFJ (2012) A human stem cell model of early Alzheimer’s disease pathology in Down syndrome. Sci Transl Med4, 124–129.
151.
CarreirasMC, MendesE, PerryMJ, FranciscoAP, Marco-ContellesJ (2013) The multifactorial nature of Alzheimer’s disease for developing potential therapeutics. Curr Top Med Chem13, 1745–1770.
152.
DiasKS, ViegasC (2014) Multi-target directed drugs: A modern approach for design of new drugs for treatment of Alzheimer’s disease. Curr Neuropharmacol12, 239–255.
